NNC0109-0012

anti-IL-20 monoclonal antibody · Novo Nordisk A/S

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NNC0109-0012, covering 2014-08-15 to 2014-08-15. Get the full timeline:

Most recent: Clinical Trial Update: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate [Phase 2]

See pricing